Li, Joey H. http://orcid.org/0000-0002-3865-5876
Zhou, Adalia
Lee, Cassidy D. http://orcid.org/0000-0002-3639-4721
Shah, Siya N.
Ji, Jeong Hyun http://orcid.org/0000-0002-7308-8774
Senthilkumar, Vignesh http://orcid.org/0009-0001-8191-8053
Padilla, Eddie T. http://orcid.org/0000-0001-8230-8719
Ball, Andréa B. http://orcid.org/0000-0002-8214-7190
Feng, Qinyan
Bustillos, Christian G.
Riggan, Luke
Greige, Alain http://orcid.org/0009-0007-0811-8416
Divakaruni, Ajit S.
Annese, Fran
Cooley Coleman, Jessica A. http://orcid.org/0000-0002-7050-8796
Skinner, Steven A.
Cowan, Christopher W.
O’Sullivan, Timothy E. http://orcid.org/0000-0003-1435-8188
Article History
Received: 17 November 2023
Accepted: 12 March 2024
First Online: 8 April 2024
Change Date: 19 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-024-01841-w
Competing interests
: T.E.O. is a scientific advisor for Modulus Therapeutics and Xyphos Biosciences, companies that have a financial interest in human NK cell-based therapeutics. The Regents of the University of California have filed a provisional patent application with the United States Patent and Trademark Office for using oleate supplementation as a method of augmenting adoptive NK cell therapy. J.H.L. and T.E.O. are listed as inventors on this patent application. The other authors declare no competing interests.